CONMED Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CONMED Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.31B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.24B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.05B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.01B | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $252.83M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $237.84M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $157.79M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $214.01M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $264.87M | Feb 22, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.31B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.24B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.05B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.01B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $862.46M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $955.10M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $859.63M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $796.39M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $763.52M | Feb 25, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $222.56M | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $190.12M | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $197.15M | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $186.57M | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $204.09M | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $184.79M | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $193.43M | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $181.20M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $191.02M | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $169.18M | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $750.48M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $733.03M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $676.25M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $571.25M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $568.04M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $135.51M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $133.70M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | $71.93M | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $119.16M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $141.98M | Feb 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.06M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $132.42M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $64.46M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | ($80.58M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $62.54M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $24.14M | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | $6.85M | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | ($27.40M) | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | $5.93M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $14.93M | Feb 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.62M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $200.33M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $120.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $70.05M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $109.72M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $46.01M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $79.11M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $71.31M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $46.94M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $37.68M | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.88M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $54.43M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $52.60M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $47.15M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $43.57M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $40.47M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $45.46M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $42.19M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $32.31M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $32.25M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $591.97M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $478.28M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $503.04M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $454.04M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $414.75M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $373.82M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $400.14M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $355.62M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $351.80M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $338.40M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.69M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $166.97M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $125.35M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $33.37M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $111.77M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $64.53M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $95.13M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $74.70M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $65.57M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $39.88M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.81M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $13.08M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $19.03M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $21.79M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $14.87M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $13.01M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $20.07M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $16.51M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $12.84M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $14.75M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.33B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.31B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.30B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.30B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.77B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.75B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.78B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.37B | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $1.36B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.33B | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.34B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.47B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.55B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $980.58M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.04B | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.06B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $706.87M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $726.53M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $748.41M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $962.68M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $834.22M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $745.55M | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $785.44M | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $709.04M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $710.47M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $662.27M | Feb 22, 2022 |
| FY2020 | Dec 31, 2017 | $631.43M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $580.58M | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $807.01M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $805.36M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $806.84M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $815.43M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $617.53M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $618.44M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $618.04M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $400.44M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $401.95M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $397.66M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.77M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $560.28M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $452.53M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $412.63M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $496.61M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $457.42M | Feb 22, 2022 |
| FY2020 | Dec 31, 2019 | $470.84M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $464.85M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $440.09M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $406.93M | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $25.86M | Feb 24, 2020 |
| FY2019 | Dec 31, 2018 | $17.51M | Feb 24, 2020 |
| FY2019 | Dec 31, 2017 | $32.62M | Feb 24, 2020 |
| FY2019 | Dec 31, 2016 | $27.43M | Feb 24, 2020 |
| FY2018 | Dec 31, 2015 | $72.50M | Feb 25, 2019 |
| FY2017 | Dec 31, 2014 | $66.33M | Feb 26, 2018 |
| FY2016 | Dec 31, 2013 | $54.44M | Feb 27, 2017 |
| FY2015 | Dec 31, 2012 | $23.72M | Feb 23, 2016 |
| FY2014 | Dec 31, 2011 | $26.05M | Feb 23, 2015 |
| FY2013 | Dec 31, 2010 | $12.42M | Feb 24, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $456.90M | Feb 25, 2019 |
| FY2018 | Dec 31, 2017 | $486.44M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $498.49M | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $270.81M | Feb 27, 2017 |
| FY2015 | Dec 31, 2014 | $241.44M | Feb 23, 2016 |
| FY2014 | Dec 31, 2013 | $215.58M | Feb 23, 2015 |
| FY2013 | Dec 31, 2012 | $161.85M | Feb 24, 2014 |
| FY2012 | Dec 31, 2011 | $143.51M | Feb 25, 2013 |
| FY2011 | Dec 31, 2010 | $195.62M | Feb 28, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 22, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 22, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.75M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $24.65M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $24.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $23.96M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $23.26M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $22.82M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $22.60M | Feb 22, 2022 |
| FY2020 | Dec 31, 2018 | $22.44M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $22.31M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $22.21M | Feb 25, 2019 |